Abstract: Here, we present a specific and novel method for treating cancer by eliciting an anti-tumor immune response in cancer patients. Specifically, this technique involves subcutaneous “auto-im-transplantation” of chimeric murine-human tumors, created in PDX mice, back to the original donor patients. This is an approach to personalized cancer therapy, which does not require identification of specific tumor associated antigens. Based on the fundamental principles of immunology, we anticipate that the autoimplanted PDX tumor will stimulate an intense immune response in the original donor patient—including activation of “xenoreactive” lymphocytes and, in turn, a “bystander” activation of anti-tumor immune response lymphocytes, which we anticipate that a response generated in this manner will become systemic and target other similar malignant cells in the patient.

Abstract: Here, we present a specific and novel method for treating cancer by eliciting an anti-tumor immune response in cancer patients. Specifically, this technique involves subcutaneous “auto-im-transplantation” of chimeric murine-human tumors, created in PDX mice, back to the original donor patients. This is an approach to personalized cancer therapy, which does not require identification of specific tumor associated antigens. Based on the fundamental principles of immunology, we anticipate that the autoimplanted PDX tumor will stimulate an intense immune response in the original donor patient—including activation of “xenoreactive” lymphocytes and, in turn, a “bystander” activation of anti-tumor immune response lymphocytes, which we anticipate that a response generated in this manner will become systemic and target other similar malignant cells in the patient.

Abstract: The invention relates to methods of preventing, treating, ameliorating and otherwise inhibiting organ or transplant rejection in a patient by administering B Lymphocyte Stimulator antagonists. In addition, therapeutic treatment regimens are provided to promote transplant tolerance in a patient following the administration of B Lymphocyte Stimulatorantagonists.

Abstract: The invention relates to methods of preventing, treating, ameliorating and otherwise inhibiting organ or transplant rejection in a patient by administering B Lymphocyte Stimulator antagonists. In addition, therapeutic treatment regimens are provided to promote transplant tolerance in a patient following the administration of B Lymphocyte Stimulatorantagonists.

Abstract: This invention is directed to a marker gene for autoimmune disease. Specifically, the invention is directed to the use of a polymorph of CD93 in methods and compositions for the detection, prognosis and therapy of Type I Diabetes and systemic lupus erythematosus (SLE).

Abstract: The invention relates to methods of preventing, treating, ameliorating and otherwise inhibiting organ or transplant rejection in a patient by administering B Lymphocyte Stimulator antagonists. In addition, therapeutic treatment regimens are provided to promote transplant tolerance in a patient following the administration of B Lymphocyte Stimulatorantagonists.

Abstract: This invention is directed to a marker gene for autoimmune disease. Specifically, the invention is directed to the use of a polymorph of CD93 in methods and compositions for the detection, prognosis and therapy of Type I Diabetes and systemic lupus erythematosus (SLE).